CBS - The 17th Left Main & Coronary Bifurcation Summit, CBS2025

CBS 2019

CBSMD教育中心

HOME
CBS 2019
At CBS

General Information

Left Main & Coronary Bifurcation Summit (CBS) was founded in 2006 as a think tank dedicated to the treatment of left main and coronary bifurcation lesions. CBS aims to improve cardiological care by refreshing fundamental researches, clinical trials, yearly published guidelines, emerged ideas and case-based discussion.

Association and Affiliations
- Organized by
  
  Nanjing Heart Center
  
  Asian Bifurcation Club (ABC)
  
  Nanjing First Hospital, Nanjing Medical University
- Co-organized by
  
  Chinese Society of Cardiology (CSC)
  
  Capacity Building and Continuing Education Center,National Health and Family Planning Commission (CBCEC)
  
  American Society for Cardiovascular Angiography and Interventions (SCAI)
  
  Asian Heart Society (AHS)
Contact Us
- Registration Administration of Domestic Representatives
  
  Hongjuan Peng : +86-13913895477
  
  Haimei Xu +86-13914736846
  
  cbsnj@cbsmd.cn
- Registration Administration of Overseas Representatives
  
  Ling Lin : +86 (25) 52271398
  
  +86-13951884596
  
  cbs@cbsmd.cn
- Management of Challenging Cases
  
  Yingying Zhao :+86-13815408517
  
  sub@cbsmd.cn
Address

CBS2019 Congress Secretariat, Nanjing First Hospital, Building No.9 68# Changle Road, Nanjing, China

210006
FACULTY
FACULTY

General Chairman
Congress Chairman
Course Directors International Faculty Domestic Faculty Hong Kong and Taiwan Faculty Members of Academic Committee
Education Center

Education Center

• Online Education (For more customized user interface with self-defined collection of research papers and education resources.)

• CBS Education Resource

• CBSMD Scientific Library
SCIENTIFIC LIBRARY

SCIENTIFIC LIBRARY

Research Paper

> Acute Coronary Syndrom

> ASCVD Prevention

> Bifurcation Stenting

> Cardio-Oncology

> Congestive Heart Failure

> DAPT Duration

> Drug Coated Balloon

> Fractional Flow Reserve

> IVUS Guidance

> Optical Coherence Tomography

> Pulmonary Hypertension

> Rotational Atherectomy

> Shear Stress

> Stenting Left Main

> Transcatheter Aortic Valve Replacement

> Percutaneous LAA Occlusion

> Mitral/Tricuspid Valvular Disease

> Other Relevant Articles

Recommended Paper

Management of Acute Myocardial Infarction During the COVID-19 Pandemic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19)

< >

HOME | SCIENTIFIC LIBRARY | DAPT Duration

DAPT Duration

Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trial Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting - A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Sort by hits |<< 1 2 3 4 5 6 7 ...>>|

Clinical Trial2015 May 21;36(20):1252-63.

JOURNAL：Eur Heart J. Article Link

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting

Schulz-Schüpke S, Byrne RA, ntracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators. Keywords: DAPT; DES; hemorrhage; myocardial infarction; polymers

FULL TEXT PDF

>CBS

CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

CBS 2019

CBS 2019 FACULTY

Education Resource

CBSMD Scientific Library